Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.34NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.34NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.34NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.34NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.34ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
CH.1.1.12ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
CH.1.1.12ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-20199.5Germany
CH.1.1.12NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
CH.1.1.12NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
CH.1.1.12NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
CH.1.1.12NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
CH.1.1.12NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
CH.1.1.12ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.9.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.9.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.9.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.9.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.9.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.9.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.9.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.9.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BN.1.4.4ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
BN.1.4.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BN.1.4.4NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BN.1.4.4NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BN.1.4.4NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BN.1.4.4NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BN.1.4.4NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BN.1.4.4ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.5.2.58ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.5.2.58ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.2.58NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.5.2.58NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.5.2.58NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.5.2.58NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.5.2.58NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.5.2.58ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XAY.2.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XAY.2.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XAY.2.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XAY.2.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XAY.2.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XAY.2.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XAY.2.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XAY.2.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.71ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.71ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.71NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.71NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.71NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used